Mucociliary clearance augmenting drugs block SARS-CoV-2 replication in human airway epithelial cells

Author:

Campos-Gómez Javier12ORCID,Fernandez Petty Courtney1,Mazur Marina12,Tang Liping12,Solomon George M.12ORCID,Joseph Reny12,Li Qian12,Peabody Lever Jacelyn E.123ORCID,Hussain Shah Saddad1ORCID,Harrod Kevin S.14,Onuoha Ezinwanne E.5ORCID,Kim Harrison6ORCID,Rowe Steven M.12ORCID

Affiliation:

1. Department of Medicine, University of Alabama at Birmingham, Alabama, United States

2. Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Alabama, United States

3. Medical Scientist Training Program, Heersink School of Medicine, University of Alabama at Birmingham, Alabama, United States

4. Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Alabama, United States

5. Department of Biomedical Engineering, University of Alabama at Birmingham, Alabama, United States

6. Department of Radiology, University of Alabama at Birmingham, Alabama, United States

Abstract

The coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2 coronavirus, is devastatingly impacting human health. A prominent component of COVID-19 is the infection and destruction of the ciliated respiratory cells, which perpetuates dissemination and disrupts protective mucociliary transport (MCT) function, an innate defense of the respiratory tract. Thus, drugs that augment MCT could improve the barrier function of the airway epithelium and reduce viral replication and, ultimately, COVID-19 outcomes. We tested five agents known to increase MCT through distinct mechanisms for activity against SARS-CoV-2 infection using a model of human respiratory epithelial cells terminally differentiated in an air/liquid interphase. Three of the five mucoactive compounds tested showed significant inhibitory activity against SARS-CoV-2 replication. An archetype mucoactive agent, ARINA-1, blocked viral replication and therefore epithelial cell injury; thus, it was further studied using biochemical, genetic, and biophysical methods to ascertain the mechanism of action via the improvement of MCT. ARINA-1 antiviral activity was dependent on enhancing the MCT cellular response, since terminal differentiation, intact ciliary expression, and motion were required for ARINA-1-mediated anti-SARS-CoV2 protection. Ultimately, we showed that the improvement of cilia movement was caused by ARINA-1-mediated regulation of the redox state of the intracellular environment, which benefited MCT. Our study indicates that intact MCT reduces SARS-CoV-2 infection, and its pharmacologic activation may be effective as an anti-COVID-19 treatment.

Funder

Cystic Fibrosis Foundation

HHS | NIH | National Heart, Lung, and Blood Institute

HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

HHS | NIH | National Institute of General Medical Sciences

Publisher

American Physiological Society

Subject

Cell Biology,Physiology (medical),Pulmonary and Respiratory Medicine,Physiology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3